Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Y0001257

Levetiracetam impurity D

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

(2R)-2-(2-Oxopyrrolidin-1-yl)butanamide, (R)-Etiracetam

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C8H14N2O2
Número de CAS:
103765-01-1
Peso molecular:
170.21
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N1(CCCC1=O)[C@H](CC)C(=O)N

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m1/s1

InChI key

HPHUVLMMVZITSG-ZCFIWIBFSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam impurity D EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

1359404

Levetiracetam, United States Pharmacopeia (USP) Reference Standard

1359437

(S)-(+)-2-Aminobutanmide hydrochloride, United States Pharmacopeia (USP) Reference Standard

1359415

Levetiracetam Racemic Mixture, United States Pharmacopeia (USP) Reference Standard

1359426

Levetiracetam Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0001253

Levetiracetam, European Pharmacopoeia (EP) Reference Standard

Y0001256

Levetiracetam impurity C, European Pharmacopoeia (EP) Reference Standard

Y0001254

Levetiracetam impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000659

Pyrrolidone, European Pharmacopoeia (EP) Reference Standard

PHR1447

Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001962

(R)-(+)-α-Methylbenzylamine, European Pharmacopoeia (EP) Reference Standard

Y0001948

(S)-(+)-2-Aminobutanmide hydrochloride, European Pharmacopoeia (EP) Reference Standard

PHR2432

(S)-(+)-2-Aminobutanmide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2428

Levetiracetam Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2417

Levetiracetam Racemic Mixture, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Exclamation markEnvironment
GHS07,GHS09

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
S Yamashita et al.
No to hattatsu = Brain and development, 45(1), 64-66 (2013-04-19)
Iu V Popov et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 113(5 Pt 2), 48-52 (2013-06-07)
We examined 76 children and adolescents (45 boys (59.2%), 31 girls (40.8%), aged from 6 to 17 years (mean age 14.31 ± 0.3), with the diagnosis of refractory epilepsy using a clinical/psychopathological method and psychometric scales. Marked non-psychotic mental disorders
Nitin K Sethi et al.
Drug metabolism and drug interactions, 28(2), 123-124 (2013-02-20)
Levetiracetam is a commonly used broad-spectrum anticonvulsant efficacious in both partial and generalized seizures. It has an extremely favorable side effect profile with few drug-drug interactions, low potential for hematological and hepatic toxicity, and thus has rapidly become the preferred
Mika H Martikainen et al.
Epileptic disorders : international epilepsy journal with videotape, 14(4), 438-441 (2012-12-19)
Epilepsy is a common manifestation of mitochondrial disease associated with mutations of the mitochondrial polymerase γ (POLG). Prognosis of mitochondrial epilepsy is often poor and there are few reports of successful treatment of POLG-related epilepsy. We describe a 26-year-old woman
Helge Bjørnæs et al.
Epilepsy & behavior : E&B, 27(1), 40-48 (2013-02-05)
We performed a double-blind placebo-controlled crossover study of the effects of spike activity during sleep and when awake on learning, long-term memory, vigilance and behavior before and after treatment with levetiracetam in children with electrical status epilepticus during sleep. At
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico